{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:42:59Z","timestamp":1793727779365,"version":"4.6.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Colorectal cancer (CRC) is commonly seen in adult patients but makes up &lt;1% of cancers in pediatric patients, with the largest known pediatric study having a sample size of 81 patients taken over a span of roughly 40 years. Patients typically present with nonspecific symptoms such as abdominal pain, nausea, and vomiting, which can result in the diagnosis being missed. Histopathology is typically unfavorable with signet ring colon cancer and mucinous adenocarcinoma with signet ring cell features being common. Treatment guidelines are based largely on adult protocols and include surgical resection followed by chemotherapy, with the addition of bevacizumab or cetuximab in higher-risk populations. In our case, we present a 17-year-old male with abdominal pain and weight loss who was found to have metastatic sporadic mucinous adenocarcinoma with signet ring cell features. Oncotype next-generation sequencing was found to be microsatellite stable, human epithelial growth factor receptor 2 negative, Kristen rat sarcoma viral oncogene homolog\/v-raf murine sarcoma viral oncogene homolog B1\/neuroblastoma reticular activating system wild type, and low tumor mutation burden with 3.7 mutations per megabase. He was treated with FOLFIRINOX at 70% dosing without bevacizumab due to recurrent admissions for small bowel obstructions and surgeries. Unfortunately, his cancer did not respond, so he proceeded with palliative chemotherapy. He expired 12 months later. This case raises the need for research on the biology of CRC in pediatric patients, as it is different from adults. It also underlines the necessity of the development of guidelines on CRC treatment in pediatric patients by initiating pediatric clinical trials or lowering the age of adult trials to under 18 years of age.<\/jats:p>","DOI":"10.1097\/mph.0000000000003031","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T13:00:09Z","timestamp":1744722009000},"page":"219-223","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Sporadic Mucinous Adenocarcinoma of the Colon in an Adolescent Male: A Case Report and Review of the Literature"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0822-9149","authenticated-orcid":false,"given":"Farrah","family":"Gaston","sequence":"first","affiliation":[{"name":"University of Illinois College of Medicine Peoria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blase","family":"Polite","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Ullenius","sequence":"additional","affiliation":[{"name":"OSF HealthCare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"OSF HealthCare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Bajaj","sequence":"additional","affiliation":[{"name":"University of Illinois College of Medicine Peoria"},{"name":"Illinois CancerCare, Peoria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"R1-20250623","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R2-20250623","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1002\/cncr.34479","article-title":"Annual report to the nation on the status of cancer, part 1: National Cancer Statistics","volume":"128","author":"Cronin","year":"2022","journal-title":"Cancer"},{"key":"R3-20250623","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.gastro.2019.07.055","article-title":"Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults","volume":"158","author":"Stoffel","year":"2020","journal-title":"Gastroenterology"},{"key":"R4-20250623","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MD.0b013e3181881354","article-title":"Young-onset colorectal cancer in patients with no known genetic predisposition: can we increase early recognition and improve outcome?","volume":"87","author":"Dozois","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"R5-20250623","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4103\/jiaps.JIAPS_33_21","article-title":"Pediatric colorectal carcinoma: a series of seven cases","volume":"27","author":"Nahajan","year":"2022","journal-title":"J Indian Assoc Pediatr Surg"},{"key":"R6-20250623","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41416-019-0548-9","article-title":"Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma","volume":"121","author":"Korphaisarn","year":"2019","journal-title":"Br J Cancer"},{"key":"R7-20250623","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.hemonc.2013.02.003","article-title":"Adenocarcinoma of the colon in children: case series and mini-review of the literature","volume":"6","author":"Al-Tonbary","year":"2013","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R8-20250623","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrclinonc.2016.199","article-title":"Surveillance after curative treatment for colorectal cancer","volume":"14","author":"van der Stok","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"R9-20250623","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11888-016-0312-y","article-title":"Molecular subtypes and personalized therapy in metastatic colorectal cancer","volume":"12","author":"Graham","year":"2016","journal-title":"Curr Colorectal Cancer Rep"},{"key":"R10-20250623","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.critrevonc.2017.08.006","article-title":"Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis","volume":"118","author":"Marques","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"R11-20250623","doi-asserted-by":"crossref","first-page":"dju427","DOI":"10.1093\/jnci\/dju427","article-title":"Primary tumor location as a prognostic factor in metastatic colorectal cancer","volume":"107","author":"Loupakis","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"R12-20250623","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.2147\/OTT.S168695","article-title":"Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type RAS metastatic colorectal cancer: a meta-analysis","volume":"1","author":"Jiang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"R13-20250623","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1634\/theoncologist.12-1-38","article-title":"The continuum of care: a paradigm for the management of metastatic colorectal cancer","volume":"12","author":"Goldberg","year":"2007","journal-title":"Oncologist"},{"key":"R14-20250623","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"R15-20250623","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"key":"R16-20250623","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/annonc\/mdu580","article-title":"Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial","volume":"26","author":"Gruenberger","year":"2015","journal-title":"Ann Oncol"},{"key":"R17-20250623","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1200\/JCO.22.00839","article-title":"Upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients with RAS\/BRAF wild-type metastatic colorectal cancer: the phase III TRIPLETE study by GONO","volume":"40","author":"Rossini","year":"2022","journal-title":"J Clin Oncol"},{"key":"R18-20250623","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1245\/s10434-014-4289-y","article-title":"Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for children, adolescents, and young adults: the first 50 cases","volume":"22","author":"Hayes-Jordan","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R19-20250623","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1200\/JCO.2007.12.6102","article-title":"Colorectal carcinoma in childhood and adolescence: a clinicopathologic review","volume":"25","author":"Hill","year":"2007","journal-title":"J Clin Oncol"},{"key":"R20-20250623","doi-asserted-by":"crossref","first-page":"pe8074","DOI":"10.1097\/MD.0000000000008074","article-title":"Two case reports: colorectal adenocarcinoma in children","volume":"96","author":"Ahn","year":"2017","journal-title":"Medicine"},{"key":"R21-20250623","first-page":"398","article-title":"Colorectal cancer in adolescence: a report of two cases","volume":"9","author":"Ayadi Masmoudi","year":"2022","journal-title":"Clin Med Rev Case Rep"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:00:38Z","timestamp":1750690838000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003031","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"2024-10-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}